14 August 2025 - Halda Therapeutics today announced that the US FDA granted fast track designation to HLD-0915, the company’s lead development candidate, for the treatment of patients with metastatic castration-resistant prostate cancer.

HLD-0915 is an innovative bifunctional small molecule therapy designed to selectively target prostate cancer tumour cells by holding together, with defined orientation and purpose, androgen receptor (a tumour-specific intracellular targeting protein) and a protein with essential function (effector protein).

Read Halda Therapeutics press release